Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for becker muscular dystrophy in early trial

NCT ID NCT05166109

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times

Summary

This study tested a drug called vamorolone in 46 males with Becker muscular dystrophy, a muscle-weakening disease. Participants took either vamorolone or a placebo daily for 24 weeks. The main goal was to check safety and side effects, while also looking at how the drug moves through the body and if it helps muscle function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BECKER MUSCULAR DYSTROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Azienda Ospedale Universita Padova

    Padova, 35129, Italy

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15261, United States

Conditions

Explore the condition pages connected to this study.